A recent randomized controlled trial to evaluate the efficacy of a fixed, short antimicrobial treatment was published in May of this year (1). This interesting study brings to the fore the importance of evaluating, with proper methodology, one of the most disputable aspects of antimicrobial treatments, the duration. When supported by strong evidence or expert statements, shortening courses of antimicrobial treatments are an important component of antimicrobial stewardship programs (2). The course of therapy must be defined as the time period during which therapeutic concentrations are maintained at the site of infection, instead of the time during which an antimicrobial treatment is administered. This definition puts emphasis on the importance of a thorough evaluation before starting a short treatment. For example, the most recent Infectious Diseases Society of America (IDSA) skin and soft tissue guidelines suggest a treatment as short as five days for cellulitis (3). This duration might not apply to a patient with cellulitis and chronic arterial insufficiency of the lower limbs. Successful abbreviated treatment courses depend on several factors linked to host (immune status), pathogen (susceptibility, low spontaneous mutation rate, extracellular, rapid multiplication), infection site (accessible site, not as biofilm, no foreign body, not life-threatening, not in an abscess − low pH, or any other factors that inhibit antimicrobial action) and therapeutic agents (bactericidal, rapid onset of action, lack of propensity to induce mutants, good penetration in tissues, active against nonresistant bacteria).

This strategy has several theoretical or demonstrated advantages. There is a clear link between bacterial resistance and shorter courses of antimicrobial treatments. It reduces the selective pressure on bacterial flora and, therefore, prevents emergence of resistance. Upper respiratory tract infections treated for ≥5 days in children increased the risk of pharyngeal carriage of resistant Streptococcus pneumoniae (4). Prophylaxis for >48 h after cardiovascular surgery was associated with increased bacterial resistance in enterobacteriaceae and enterococci (5). However, one must remember that a useless short course is still the worst strategy and strength should also be put on avoiding the treatment of conditions that do not require antimicrobial treatments such as asymptomatic bacteriuria, upper respiratory viral infections and viral otitis media, etc.

Other advantages of short therapy are increased compliance, reduced direct (related to the acquisition of an antimicrobial treatment) and indirect (associated with administration of intravenous antimicrobial treatments, adverse effects, length of stay, etc) costs, lower risk of adverse events and drug-drug interactions. The main drawback of a shorter treatment is the risk of lower efficacy that may be associated with additional treatment (probably with a broader spectrum because the patient failed the previous treatment), significant morbidity and hospital admissions/readmissions. There is a lower limit under which short therapy becomes ineffective and that is why we need sound studies to support it. Several studies have demonstrated the limit in shortening treatments because they were associated with unfavourable outcomes. Single-dose treatments for uncomplicated cystitis have been consistently shown to be less successful than longer courses (6) and treating Staphylococcus aureus bacteremia for <14 days was associated with higher relapse rates (7).

In the 2010, Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America, the recommended duration of an established infection was four to seven days in patients with adequate source control (8). At this time, it was graded as a B-III (moderate evidence coming mainly from expert opinion and descriptive studies). For some indications, suggested treatment or prophylaxis was even shorter. For stomach or proximal jejunum perforations, when source control was achieved, prophylactic antibiotics directed against aerobic Gram-positive cocci for 24 h were considered to be adequate, unless patients were undergoing treatment to reduce gastric acidity or were known for gastric malignancy. In these cases, antimicrobial therapy covering a mixed flora was recommended for the same duration. Penetrating bowel injuries repaired within 12 h, any intraoperative contamination by enteric contents, acute appendicitis without perforation, and abscess or local peritonitis should be treated with an antimicrobial treatment with mixed flora coverage for 7–14 days.

The recent multicentre randomized controlled trial published by Sawyer et al (1) presents evidence to support a four-day treatment for complicated intra-abdominal infections, instead of the four to seven days suggested in the aforementioned guidelines. A total of 518 patients were enrolled and underwent randomization; 260 were assigned to a control group that received antimicrobial treatments until two days after the resolution of their sepsis (based on systemic inflammatory response syndrome criteria) and 258 received a fixed four-day course of therapy. To be included in the study, patients needed to have undergone an intervention to achieve source control. The choice of the antimicrobial agent was not dictated by the protocol but was considered acceptable if consistent with IDSA guidelines. The most frequently used antimicrobial treatment was piperacillin-tazobactam in 54% of patients. Baseline characteristics in the two groups were very similar. In the control group, patients received antimicrobial treatments for a median duration of eight days (interquartile range five to 10 days) versus four days (interquartile range four to five days) in the experimental group. The main outcomes of this study, surgical site infection and recurrent intra-abdominal infection or death, were almost identical in both groups; 21.8% in the experimental group versus 22.3% in the control group (absolute difference −0.5 percentage point [95 % CI −7.0 to 8.0] [P=0.92]). The study had several strengths including a large sample size and randomized design, but above all, it included patients with...
different severities of illness and methods for source control (percutaneous versus surgical). Authors report several limitations: results are applicable only to immunocompetent patients with adequate source control; there was an important rate of nonadherence to the protocol in both groups creating a bias toward the null hypothesis; and the sample size to assert equivalence between groups was not reached. However, this is the best study available because it brings appreciable additional evidence to limit the duration of antimicrobial treatment to four days in similar patients. Hopefully, this study will achieve higher impact than the IDSA guidelines, because recent data show that patients with intra-abdominal infections are treated for a mean duration of 10 to 14 days (9).

Even if it is a very imprecise science, most IDSA guideline authors have made an important effort to delineate the best duration of treatment for most infections. As you will see, these recommendations are frequently supported by low- to moderate-quality evidence (Table 1).

Most of the IDSA guidelines have been published for more than five years. Consequently, in the updated version, new shorter options may be available and the level of evidence to support some of the current recommendations may be stronger. Several studies aiming to evaluate shorter antimicrobial treatments are recruiting (www.clinicaltrials.gov). Of interest, seven versus 14 days comparison for bloodstream infections caused by enterobacteriaceae, (SHORTEN study) two days versus seven days versus two to seven days based on C-reactive protein monitoring in the treatment of acute exacerbations of chronic obstructive pulmonary disease, and seven versus 14 days for patients admitted in the intensive care unit with bacteremia (BALANCE study). The latter is a multicentre randomized controlled trial being conducted in 13 hospitals in Canada. The results of this study will be particularly interesting because it aims to enroll patients with bacteremia from different sources. It is also remarkable that a group of Canadian researchers are leaders in this domain. The selection of the optimal duration of prescription remains and is largely an art rather than a science, and additional trials are needed to continue to identify the best duration of antimicrobial treatment and maximize efficacy by lowering the associated side effects.

### TABLE 1
Shorter recommended treatment for frequent infections in adults seen in hospitals, from the Infectious Diseases Society of America guidelines

| Type of infectious disease | Suggested treatment duration | Suggested clinical criteria/comments | Grading of evidence | Year of publication |
|----------------------------|------------------------------|--------------------------------------|---------------------|---------------------|
| Intraocular infections     |                              |                                      |                     |                     |
| Catheter-related bloodstream infections (10) | 5–7 days | Coagulase-negative *Staphylococcus* species with catheter removal | B-III, moderate evidence from expert opinion and descriptive studies | 2009 |
|                             | 10–14 days | Coagulase-negative *Staphylococcus* species + antibiotic lock therapy if catheter is retained |                     |                     |
|                             | 7–14 days | *Enterococcus* species, Gram-negative bacilli | C-III, poor evidence from expert opinion and descriptive studies |                     |
|                             | 14 days | For *Staphylococcus* aureus and *Staphylococcus lugdunensis* 14 days can be considered if: not diabetic; immunocompetent; catheter is removed; no prosthetic intravascular device; no evidence of endocarditis; no metastatic foci of infection; and fever and bacteremia are resolved within 72 h of antimicrobial initiation | A-II, good evidence from at least one RCT or high-quality observational studies |                     |
|                             | 4–6 weeks | *S aureus* and *S lugdunensis* with positive criteria for shorter duration | B-II, moderate evidence from at least one RCT or high-quality observational studies | 2005 |
| Endocarditis (11)          | 14 days | Combination therapy (Penicillin/ceftriaxone + gentamicin) for viridans group and *Streptococcus bovis* (MIC ≤0.5 μg/mL) | IB, general agreement, data derived from a single RCT or nonrandomized studies | 2005 |
|                            | 4 weeks | Viridans group and *S bovis* (MIC ≤0.5 μg/mL) with penicillin or ceftriaxone monotherapy | IA, general agreement, data derived from multiple RCTs | 2007 |
|                            | 6 weeks | Enterococcal-native valve endocarditis susceptible to penicillin and gentamicin + symptoms of illness ≤3 months | IA, general agreement, data derived from multiple RCTs | 2008 |
| Lower/upper respiratory infections | 5–7 days | Uncomplicated acute bacterial rhinosinusitis, might not apply to elderly with underlying illnesses and patients with immunosuppression | Weak recommendation, low- to moderate-quality evidence | 2012 |
| Acute bacterial rhinosinusitis (12) | 5 days | Afebrile for 48–72 h | Weak recommendation, low- to moderate-quality evidence | 2012 |
| Community-acquired pneumonia (13) | 5 days | Not more than one of: heart rate >100/min; respiratory rate >24/min; systolic blood pressure <90 mmHg; arterial O2 saturation of <90% on room air; able to maintain oral intake; normal mental status | Level 1 (high) | 2007 |

Continued on next page
## TABLE 1 – CONTINUED
Shorter recommended treatment for frequent infections in adults seen in hospitals, from the Infectious Diseases Society of America guidelines

| Type of infectious disease                              | Suggested treatment duration | Suggested clinical criteria/comments                                                                 | Grading of evidence                                                                 | Year of publication |
|---------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------|
| Lower/upper respiratory infections – CONTINUED           |                              |                                                                                                       |                                                                                    |                     |
| Hospital-associated pneumonia, ventilator-associated pneumonia and health care-associated pneumonia (14) | 7 days                       | Initially appropriate therapy, good clinical response                                                | Evidence from well-conducted, randomized controlled trials                           | 2005                |
|                                                          | 14 days                      | Nonfermenting Gram-negative bacilli                                                                  |                                                                                    |                     |
| Skin and soft tissue infections (3)                     |                              |                                                                                                       |                                                                                    |                     |
| Nonpurulent sexually transmitted infection              | 5 days                       | Might be extended if the infection has not improved within this time period                           | Strong recommendation, high-quality evidence                                         | 2014                |
| Impetigo/echtyma                                        | 7 days                       | Oral treatment is suggested in patients with numerous lesions and during outbreaks                    | Strong recommendation, moderate-quality evidence                                    |                     |
| Pyomyositis                                             | 14 days                      |                                                                                                       | Strong recommendation, low-quality evidence                                        |                     |
| Urinary tract infection                                 |                              |                                                                                                       |                                                                                    |                     |
| Catheter-associated urinary tract infection (15)        | 3 days                       | Women, without upper urinary tract infection symptoms, indwelling catheter removed                    | B-II, moderate evidence from at least one RCT or high-quality observational study   | 2010                |
|                                                          | 5 days                       | Levofloxacin 750 mg in patients not severely ill                                                     | B-III, moderate evidence from expert opinion and descriptive studies                |                     |
|                                                          | 7 days                       | All patients with prompt resolution of symptoms                                                       | A-III, strong evidence from expert opinion and descriptive studies                  |                     |
|                                                          | 10–14 days                   | All patients with delayed response                                                                   |                                                                                    |                     |
| Uncomplicated cystitis (16)                             | 1 day                        | Fosfomycin 3 g                                                                                        | A-I (except β-lactam that are graded B-I), good evidence from more than one RCT     | 2011                |
|                                                          | 3 days                       | Quinolones, TMP-SMX, β-lactam agents (3–7 days)                                                      |                                                                                    |                     |
|                                                          | 5 days                       | Nitrofurantoin                                                                                        |                                                                                    |                     |
| Uncomplicated Pyelonephritis (16)                        | 5 days                       | Levofloxacin 750 mg daily                                                                            | B-II, moderate evidence from expert opinion and descriptive studies                 |                     |
|                                                          | 7 days                       | Ciprofloxacin 1000 mg daily                                                                          |                                                                                    |                     |
|                                                          | 14 days                      | TMP-SMX double strength twice-daily, β-lactam agents (10–14 days)                                    | A-I (TMP-SMX), good evidence from more than one RCT                                 |                     |
| Others                                                  |                              |                                                                                                       |                                                                                    |                     |
| Bacterial meningitis (17)                               | 7 days                       | Neisseria meningitidis and Haemophilus influenzae                                                     | A-III, strong evidence coming mainly from expert opinion and descriptive studies   | 2004                |
|                                                          | 10 days                      | Streptococcus pneumoniae                                                                             |                                                                                    |                     |
|                                                          | 14 days                      | Streptococcus agalactiae                                                                              |                                                                                    |                     |
|                                                          | 21 days                      | Listeria monocytogenes and aerobic Gram-negative bacilli                                             |                                                                                    |                     |
| Complicated intra-abdominal infection (8)               | 4–7 days                     | Patients with adequate source control                                                                | B-III, moderate evidence coming mainly from expert opinion and descriptive studies | 2010                |

**REFERENCES**

1. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intra-abdominal infection. N Engl J Med 2015;372:1996-2005.
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
3. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:147-59.
4. Guilmot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-70.
5. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916-21.
6. Nicolle LE. Short-term therapy for urinary tract infection: Success and failure. Int J Antimicrob Agents 2008;31(Suppl 1):S40-5.
7. Chong YP, Moon SM, Bang KM, et al. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: Analysis of a prospective observational cohort study. Antimicrob Agents Chemother 2013;57:1190-6.
8. Solomkin JS, Maziak JE, Braddey JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64.
9. Riccio LM, Popovsky KA, Hranjec T, et al. Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: A study of 2,552 consecutive infections. Surg Infect (Larchmt) 2014;15:417-24.
10. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52:e162-93.
11. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434.

12. Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54:e72-e112.

13. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.

14. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.

15. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-63.

16. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.

17. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.